查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014459

数位治疗设备市场：2026-2032年全球市场预测（按治疗领域、给药方法、分销管道和最终用户划分）

Digital Therapeutic Devices Market by Therapeutic Area, Delivery Mode, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，数位治疗设备市场价值将达到 87.1 亿美元，到 2026 年将成长至 102.4 亿美元，到 2032 年将达到 296.2 亿美元，复合年增长率为 19.10%。

主要市场统计数据
基准年 2025 87.1亿美元
预计年份：2026年 102.4亿美元
预测年份 2032 296.2亿美元
复合年增长率 (%) 19.10%

权威说明指出，临床检验、监管演变和支付方合作正在重新定义数位治疗设备，以实现可持续的临床整合。

在软体开发、感测器技术和实证设计进步的推动下，数位治疗设备已从实验性介入措施发展成为经临床检验的工具，成为传统诊疗路径的有力补充。近年来，法律规范日趋成熟，已将软体视为医疗设备，支付方也开始认识到其在改善临床疗效和降低后续成本方面的提案。因此，产品开发的重点已转向产生严谨的临床证据、确保与电子医疗系统的互通性以及展现长期的病人参与。

人工智慧驱动的个人化、身临其境型交付模式和基于价值的报销如何融合，从而从根本上改变数位疗法的采用、开发和临床整合？

在技​​术突破和医疗保健系统变革的推动下，数位治疗设备领域正经历着一场变革。人工智慧 (AI) 和机器学习正在实现可随时间推移而调整的个人化治疗方案。同时，感测器精确度的提高和穿戴式装置的进步使得持续生理监测成为可能，从而增强了患者的参与度和临床相关性。诸如虚拟实境 (VR) 和扩增实境(AR) 等身临其境型技术正在拓展治疗方法，超越传统的行动应用程序，为疼痛管理、认知训练和暴露疗法提供了新的治疗机制。

评估 2025 年关税调整对数位治疗设备製造商的供应链韧性、筹资策略和定价方法的策略影响。

2025年新关税措施的实施，为数位治疗设备价值链上的相关人员带来了新的营运和策略考量。对于依赖硬体的设备和从海外供应商采购的感测器组件而言，供应链成本趋势尤其显着。因此，各公司正在探索替代筹资策略，例如供应商多元化、协商成本分摊安排以及区域製造伙伴关係，以在不影响临床规格的前提下维持获利能力。

透过详细的細項分析，阐明目标族群、剂型、最终用户环境和分销策略如何共同决定引入途径和临床影响。

细分市场层面的趋势揭示了不同治疗领域、剂型、终端用户和分销管道的不同发展机会。在治疗领域方面，专注于心臟衰竭和高血压的循环系统解决方案因其明确的临床终点和与医疗团队的频繁互动而发展势头强劲；而针对1型和2型糖尿病的糖尿病管理解决方案则受益于与持续血糖监测和自动化胰岛素输注系统的紧密整合。针对焦虑、忧郁症和压力管理的心理健康产品需求旺盛，这主要得益于扩充性的远距交付。同时，用于治疗慢性疼痛和进行物理復健的肌肉骨骼介入措施正透过客观的功能评估指标和远端监测展现其价值。用于治疗气喘和慢性阻塞性肺病（COPD）的呼吸系统疗法正利用与联网吸入器和肺功能仪的整合来提高患者的用药依从性并预防病情加重。

美洲、欧洲、中东和非洲以及亚太地区的区域战略挑战和实施模式，这些挑战和模式会影响监管、商业和製造战略。

区域趋势差异显着，影响开发商、支付方和医疗服务提供者的策略重点。在美洲，监管政策的明确化和基于价值的医疗试点计画生态系统的不断发展，促进了与支付方和医疗系统的合作，同时，支持将设备和软体整合到慢性病管理中的商业性报销途径也日趋成熟。在欧洲、中东和非洲，各国法规结构和报销政策的差异，使得制定区域性监管策略和有针对性的卫生经济学证据成为必要，以确保成功部署；与大学附属医院的合作通常能够提升试验计画的可信度和部署效率。在亚太地区，数位医疗的快速普及、行动网路的广泛应用以及製造群带来了规模经济效益，但成功的商业化需要应对不同的管理体制，并实现语言和临床路径的本地化。

不断发展的竞争策略、策略联盟和基于证据的差异化正在重塑数位治疗设备公司的产品定位和经营模式。

数位治疗设备领域的竞争格局呈现出成熟医疗设备製造商、数位医疗Start-Ups以及来自消费科技​​公司的跨产业企业并存的局面。主要企业正努力透过提供临床证据、建立可扩展的平台架构以及与製药公司和医疗系统建立策略合作伙伴关係来脱颖而出，旨在将其产品整合到标准治疗流程中。创业投资支援的创新者往往专注于快速迭代开发和特异性疾病的适应症，而成熟製造商则利用其监管方面的专业知识和供应链规模来加速软硬体整合产品的市场推广。

为高阶主管提供可操作且优先考虑的建议，以协调临床证据、互通性、供应链弹性和经营模式，以实现永续成长。

行业领导企业必须推动一系列综合倡议，以确保临床应用和商业性成功。首先，他们应优先创建符合支付方和医疗服务提供者决策标准的可靠临床证据，利用可操作的试验设计和真实世界数据来证明有意义的长期疗效。其次，他们应设计可与电子健康记录和临床工作流程整合的互通性解决方案，以减轻临床医生的负担并实现无缝资料交换。第三，他们应建构灵活的经营模式，包括基于疗效的合约、与医疗系统试验计画以及反映部署环境的分级定价。

为了检验策略意义，我们采用了严格的混合方法研究，结合了专家访谈、临床证据整合、监管分析和情境测试。

本分析所依据的研究采用了混合方法，结合了质性访谈、二手证据整合以及针对性的供应链和监管分析。访谈对象涵盖了广泛的相关人员，包括临床医生、保险公司、采购经理、医疗设备开发商和技术合作伙伴，旨在深入了解推广应用的障碍和驱动因素。二手分析则仔细审查了同行评审的临床研究、监管指导文件、互通性技术标准以及公开的临床试验註册信息，以整合有关疗效、安全性和推广应用考虑的证据。

一项综合临床、监管和营运重点的最终结论，将决定数位治疗设备的领导地位和永续应用。

总之，数位治疗设备领域正日趋成熟，成为一个以临床为主导且具有商业性可行性的医疗保健服务分支，但成功需要证据、法规和商业策略的严格协调。那些投资于严谨的临床检验、注重互通性设计以及与支付方合作的商业模式的开发商，将比竞争对手更具优势。同时，供应链的韧性和本地化策略对于缓解贸易相关的成本压力、确保生产和分销的连续性至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：数位治疗设备市场：依治疗领域划分

  • 循环系统
    • 心臟衰竭
    • 高血压
  • 糖尿病管理
    • 1型糖尿病
    • 2型糖尿病
  • 心理健康
    • 焦虑
    • 忧郁症
    • 压力管理
  • 肌肉骨骼系统
    • 慢性疼痛
    • 物理復健
  • 呼吸系统
    • 气喘
    • COPD

第九章：数位医疗器材市场：以交付方式划分

  • 移动的
  • 虚拟实境/扩增实境
  • 穿戴式装置
  • Web

第十章：数位治疗设备市场：依通路划分

  • 离线
  • 线上平台

第十一章：数位治疗设备市场：以最终用户划分

  • 家庭环境
  • 医院和诊所
  • 研究机构

第十二章：数位治疗设备市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：数位治疗设备市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 数位治疗设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国数位治疗设备市场

第十六章：中国数位医疗设备市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 2Morrow, Inc.
  • Akili Interactive Labs, Inc.
  • Big Health Ltd.
  • Biofourmis, Inc.
  • Canary Health, Inc.
  • Click Therapeutics, Inc.
  • CureApp, Inc.
  • DarioHealth Corp.
  • Kaia Health Software GmbH
  • MindMaze SA
  • Noom, Inc.
  • Omada Health, Inc.
  • Pear Therapeutics, Inc.
  • Propeller Health, Inc.
  • Teladoc Health, Inc.
  • Vida Health, Inc.
  • WellDoc, Inc.
Product Code: MRR-4348D129FA64

The Digital Therapeutic Devices Market was valued at USD 8.71 billion in 2025 and is projected to grow to USD 10.24 billion in 2026, with a CAGR of 19.10%, reaching USD 29.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.71 billion
Estimated Year [2026] USD 10.24 billion
Forecast Year [2032] USD 29.62 billion
CAGR (%) 19.10%

An authoritative introduction to how clinical validation, regulatory evolution, and payer alignment are redefining digital therapeutic devices for durable clinical integration

Digital therapeutic devices have evolved from experimental interventions to clinically validated tools that complement traditional care pathways, driven by advances in software development, sensor technology, and evidence-based design. In recent years, regulatory frameworks have matured to accommodate software as a medical device, and payer ecosystems have begun to recognize value propositions tied to improved clinical outcomes and reduced downstream costs. Consequently, product development priorities have shifted toward generating rigorous clinical evidence, ensuring interoperability with electronic health systems, and demonstrating long-term patient engagement.

As a result, commercialization strategies increasingly center on partnerships with health systems, payers, and pharmaceutical companies to embed therapeutics into standard care pathways. This trend has been reinforced by clinicians adopting digital therapeutics as adjunctive therapies to address chronic disease management challenges that are not fully resolved by pharmacological interventions alone. Looking ahead, developers who can align clinical validation, regulatory strategy, and reimbursement readiness will realize faster adoption curves and deeper integration into care delivery models. Transitional investments in privacy architecture, real-world evidence generation, and clinician-facing workflows are becoming non-negotiable to unlock durable commercial traction.

How AI personalization, immersive delivery modes, and value-based reimbursement are converging to fundamentally shift adoption, development, and clinical integration of digital therapeutics

The landscape for digital therapeutic devices is undergoing transformative shifts shaped by technological breakthroughs and systemic healthcare changes. Artificial intelligence and machine learning are enabling personalized therapeutic pathways that adapt over time, while advances in sensor fidelity and wearable form factors allow continuous physiological monitoring that enhances both engagement and clinical relevance. Immersive technologies such as virtual and augmented reality are expanding therapeutic modalities beyond traditional mobile applications, offering novel treatment mechanisms for pain modulation, cognitive retraining, and exposure-based therapies.

Concurrently, value-based care initiatives and outcome-driven reimbursement models are incentivizing stakeholders to adopt solutions that demonstrably improve care quality and reduce avoidable utilization. This alignment between clinical outcomes and commercial incentives is catalyzing strategic partnerships across the health ecosystem. Furthermore, growing patient expectations for convenient, home-based care are accelerating adoption of remote delivery modes, and interoperability standards are increasingly critical to ensure seamless integration with provider workflows. Taken together, these shifts are elevating clinical robustness, scalability, and the imperative for measurable real-world impact.

Assessing the strategic consequences of 2025 tariff adjustments on supply chain resilience, sourcing strategies, and pricing approaches across digital therapeutic device manufacturers

The imposition of new tariff measures in 2025 has introduced a fresh set of operational and strategic considerations for stakeholders in the digital therapeutic device value chain. Supply chain cost dynamics have become more prominent, particularly for hardware-dependent devices and sensor components sourced from overseas suppliers. Consequently, companies are evaluating alternative sourcing strategies, including supplier diversification, negotiated cost-sharing arrangements, and regional manufacturing partnerships to preserve margin structures without compromising clinical specifications.

In reaction to tariff-driven cost pressures, manufacturers are prioritizing design for manufacturability and component consolidation to reduce dependence on tariff-exposed inputs. In parallel, commercial teams are reassessing pricing approaches and contracting models to maintain payer and provider uptake while mitigating the risk of price-driven adoption slowdowns. Importantly, tariff impacts are not uniformly distributed; companies that can localize critical production steps or vertically integrate key components gain resilience and a competitive edge. Thus, strategic supply chain planning, contract flexibility, and early engagement with procurement and regulatory stakeholders are proving essential to navigate the evolving trade environment.

Deep segmentation insights revealing how therapeutic focus, delivery modality, end-user environment, and distribution strategy collectively determine adoption pathways and clinical impact

Segment-level dynamics reveal differentiated opportunity paths across therapeutic areas, delivery modes, end users, and distribution channels. Within therapeutic areas, cardiovascular solutions focused on heart failure and hypertension are gaining traction due to clear clinical endpoints and frequent touchpoints with care teams, whereas diabetes management solutions targeting type 1 and type 2 diabetes benefit from tight integration with continuous glucose monitoring and automated insulin delivery ecosystems. Mental health offerings addressing anxiety, depression, and stress management are experiencing strong demand driven by scalable remote delivery, while musculoskeletal interventions for chronic pain and physical rehabilitation demonstrate value through objective functional measures and remote monitoring. Respiratory therapies for asthma and COPD are leveraging connected inhaler and spirometry integrations to support adherence and exacerbation prevention.

Delivery mode is shaping user engagement and therapeutic mechanism: mobile-first applications provide ubiquitous access and broad reach, VR and AR solutions enable immersive therapeutic exposures and neurocognitive retraining, wearable devices support continuous physiologic measurement and closed-loop interventions, and web platforms offer clinician dashboarding and program management at scale. End-user environments influence design and deployment: solutions optimized for home settings prioritize ease of use, security, and asynchronous clinician interaction; hospital and clinic implementations demand integration with clinical workflows and rigorous validation; research institute deployments emphasize modular data export and protocol adherence. Distribution channels remain bifurcated between offline pathways, which rely on provider referral and institutional contracting, and online platforms that enable direct-to-consumer access and subscription models. Successful offerings typically combine a clear therapeutic rationale with delivery modes matched to the intended end-user environment and a distribution strategy that balances clinical endorsement with consumer access.

Regional strategic imperatives and adoption patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence regulatory, commercial, and manufacturing strategies

Regional dynamics vary substantially and shape strategic priorities for developers, payers, and providers. In the Americas, regulatory clarity and a growing ecosystem of value-based care pilots incentivize partnerships with payers and health systems, while commercial reimbursement pathways are maturing to support device and software integration into chronic care management. In Europe, Middle East & Africa, heterogeneity across national regulatory frameworks and reimbursement policies necessitates localized regulatory strategies and targeted health economic evidence to secure adoption, and collaborations with academic medical centers often support credibility and pilot program deployment. In Asia-Pacific, rapid digital health uptake, robust mobile penetration, and manufacturing clusters offer scale advantages, yet successful commercialization requires navigation of diverse regulatory regimes and localization of language and clinical pathways.

Across regions, differences in digital health literacy, clinician acceptance, and infrastructure maturity influence adoption speed. Cross-border partnerships, regional manufacturing, and localized evidence generation are common responses to these variations. Furthermore, regulatory convergence efforts and international standards for interoperability are creating opportunities for solutions that can be efficiently adapted across multiple jurisdictions. Companies that develop flexible regulatory plans and region-specific engagement strategies are best positioned to capture global opportunities while addressing local clinical and payer expectations.

How evolving competitive strategies, strategic alliances, and evidence-driven differentiation are reshaping product positioning and commercial models among digital therapeutic device companies

Competitive dynamics in the digital therapeutic devices space are characterized by the coexistence of established medical device manufacturers, digital health startups, and cross-sector entrants from consumer technology firms. Leading organizations are differentiating through clinical evidence generation, scalable platform architectures, and strategic alliances with pharmaceutical companies and health systems to embed products into standard care pathways. Venture-backed innovators often focus on rapid iteration and disease-specific indications, while incumbent manufacturers leverage regulatory know-how and supply chain scale to accelerate market entry for hybrid hardware-software offerings.

Strategic M&A and partnership activity is reshaping capability portfolios, with acquirers seeking assets that provide clinical validation, regulatory clearance, and established distribution relationships. Intellectual property strategies increasingly emphasize data models, algorithms, and integrated care pathways, and companies are investing in real-world evidence platforms to demonstrate longitudinal outcomes. As a result, business models are evolving from point-solution sales to subscription-based offerings, outcome-linked contracts, and bundled therapy packages that align incentives across stakeholders. Companies that can combine rigorous clinical proof, operational scalability, and payer-aligned value propositions will maintain differentiated positioning in an increasingly competitive landscape.

Actionable, prioritized recommendations for executives to align clinical evidence, interoperability, supply chain resilience, and commercial models for sustained growth

Industry leaders must pursue an integrated set of actions to secure clinical adoption and commercial success. First, prioritize generation of robust clinical evidence that aligns with payer and provider decision criteria, using pragmatic trial designs and real-world data to demonstrate meaningful outcomes over time. Second, design interoperable solutions that integrate with electronic health records and clinical workflows to reduce friction for clinicians and enable seamless data exchange. Third, develop flexible commercial models that include outcome-based contracting, pilot programs with health systems, and tiered pricing to reflect deployment contexts.

In addition, strengthen supply chain resilience through diversified sourcing, regional manufacturing partnerships, and component standardization to mitigate tariff and logistics risks. Invest in privacy-preserving data architectures and transparent consent mechanisms to build trust with patients and providers. Cultivate clinician champions and embed training resources to accelerate uptake, and deploy patient engagement strategies that combine behavioral science with usability testing to sustain adherence. Finally, engage early with regulatory bodies and payers to align evidence generation plans with reimbursement requirements, and consider strategic collaborations with pharmaceutical companies to leverage existing distribution channels and clinical trial infrastructure.

A rigorous mixed-methods research approach combining expert interviews, clinical evidence synthesis, regulatory analysis, and scenario testing to validate strategic implications

The research underpinning this analysis employed a mixed-methods approach combining primary qualitative interviews, secondary evidence synthesis, and targeted supply chain and regulatory analysis. Interviews were conducted with a cross-section of stakeholders including clinicians, payers, procurement leaders, device developers, and technology partners to capture practical insights into adoption barriers and enablers. Secondary analysis reviewed peer-reviewed clinical studies, regulatory guidance documents, technical standards for interoperability, and publicly available clinical trial registries to synthesize evidence on efficacy, safety, and implementation considerations.

Scenario analyses were used to explore the implications of supply chain disruptions and policy changes, while comparator mapping assessed differences in delivery modes and end-user contexts. The methodology emphasized triangulation of sources to validate themes and identify convergent findings. Quality assurance protocols included source verification and expert review to ensure that strategic implications are grounded in reliable clinical and operational evidence. Where evidence gaps were identified, they were explicitly noted as priorities for further empirical research and pilot deployments.

A decisive conclusion synthesizing clinical, regulatory, and operational priorities that determine leadership and sustained adoption in digital therapeutic devices

In conclusion, the digital therapeutic device landscape is maturing into a clinically driven and commercially viable segment of healthcare delivery, but success requires a disciplined alignment of evidence, regulation, and commercial strategy. Developers who invest in rigorous clinical validation, design for interoperability, and build payer-aligned commercial models will outpace competitors. At the same time, supply chain resilience and localization strategies are essential to mitigate trade-related cost pressures and ensure continuity of production and distribution.

Collaboration across stakeholders-including clinicians, payers, technology partners, and regulators-will accelerate integration of digital therapeutics into standard care pathways. Organizations that proactively address privacy, clinician adoption, and long-term real-world outcomes will not only meet regulatory and payer expectations but also deliver measurable patient benefit. Ultimately, a focus on demonstrable clinical value, scalable operational models, and adaptive regulatory strategies will determine which players lead the next phase of adoption and contribute to sustainable improvements in chronic disease management and population health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Digital Therapeutic Devices Market, by Therapeutic Area

  • 8.1. Cardiovascular
    • 8.1.1. Heart Failure
    • 8.1.2. Hypertension
  • 8.2. Diabetes Management
    • 8.2.1. Type 1 Diabetes
    • 8.2.2. Type 2 Diabetes
  • 8.3. Mental Health
    • 8.3.1. Anxiety
    • 8.3.2. Depression
    • 8.3.3. Stress Management
  • 8.4. Musculoskeletal
    • 8.4.1. Chronic Pain
    • 8.4.2. Physical Rehabilitation
  • 8.5. Respiratory
    • 8.5.1. Asthma
    • 8.5.2. Copd

9. Digital Therapeutic Devices Market, by Delivery Mode

  • 9.1. Mobile
  • 9.2. Vr Ar
  • 9.3. Wearable
  • 9.4. Web

10. Digital Therapeutic Devices Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online Platforms

11. Digital Therapeutic Devices Market, by End User

  • 11.1. Home Settings
  • 11.2. Hospitals And Clinics
  • 11.3. Research Institutes

12. Digital Therapeutic Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Digital Therapeutic Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Digital Therapeutic Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Digital Therapeutic Devices Market

16. China Digital Therapeutic Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 2Morrow, Inc.
  • 17.6. Akili Interactive Labs, Inc.
  • 17.7. Big Health Ltd.
  • 17.8. Biofourmis, Inc.
  • 17.9. Canary Health, Inc.
  • 17.10. Click Therapeutics, Inc.
  • 17.11. CureApp, Inc.
  • 17.12. DarioHealth Corp.
  • 17.13. Kaia Health Software GmbH
  • 17.14. MindMaze SA
  • 17.15. Noom, Inc.
  • 17.16. Omada Health, Inc.
  • 17.17. Pear Therapeutics, Inc.
  • 17.18. Propeller Health, Inc.
  • 17.19. Teladoc Health, Inc.
  • 17.20. Vida Health, Inc.
  • 17.21. WellDoc, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ANXIETY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ANXIETY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ANXIETY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY STRESS MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY STRESS MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY STRESS MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY PHYSICAL REHABILITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY PHYSICAL REHABILITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY PHYSICAL REHABILITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COPD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COPD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COPD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MOBILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MOBILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MOBILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY VR AR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY VR AR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY VR AR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY WEARABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY WEARABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY WEARABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY WEB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY WEB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY WEB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HOME SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HOME SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HOME SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 180. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 181. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 182. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 183. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. GCC DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 210. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 211. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 212. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 213. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. G7 DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 221. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 222. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 223. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. NATO DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MENTAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY MUSCULOSKELETAL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA DIGITAL THERAPEUTIC DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)